Treatment
Sintilimab clinical trials
We’re tracking 172 recruiting studies that include Sintilimab, each written for real people, not researchers, below.
Recruiting studies
- NCT06341595RecruitingPhase 2
Chemo, radiation and immunotherapy before surgery for stomach cancer with PALM
This trial tests combining chemotherapy, radiation, and an immunotherapy drug (sintilimab) before surgery for advanced stomach cancer that has spread to lymph nodes near the aorta (called PALM). The goal is to see if this approach can shrink the tumor enough to allow complete removal.
Nanjing, JiangsuAges 18–75 - NCT06421298RecruitingPhase 2
Tafolecimab and sintilimab plus chemo for advanced lung cancer
This trial is testing a new combination of treatments, including an immune drug (sintilimab) and a cholesterol-lowering drug (tafolecimab), along with chemotherapy, for people with advanced lung cancer that no longer responds to standard immunotherapy.
Beijing, Beijing MunicipalityAges 18–75 - NCT06463834RecruitingPhase 2
Sintilimab plus chemo before surgery for esophageal cancer
This study tests a combination of an immunotherapy drug (sintilimab) with chemotherapy given before surgery for a type of esophageal cancer called squamous cell carcinoma. The goal is to see if this treatment shrinks the tumor and improves outcomes.
Fuzhou, FujianAges 18–75 - NCT07831993RecruitingPhase 2
Immunotherapy with chemotherapy for advanced bile duct cancer
This trial tests a new combination of a drug that helps your immune system fight cancer, called sintilimab, along with chemotherapy. It is for people who have bile duct cancer or gallbladder cancer that has spread to other parts of the body and have not had treatment for this stage yet. The goal is to see if this combination helps shrink tumors or stops them from growing.
Nanjing, JiangsuAges 18–75 - NCT06138028RecruitingPhase 2/Phase 3
Sintilimab plus chemo and radiation for advanced esophageal cancer
This trial tests a combination of an immunotherapy drug (sintilimab) plus chemotherapy followed by radiation therapy for advanced esophageal cancer that has spread. The goal is to see if this sequence can help shrink tumors and improve outcomes.
Qingdao, ShandongAges 18–80 - NCT07797816RecruitingPhase 2
Targeted drug combo with radiation for advanced bile duct cancer
This trial tests a combination of two chemotherapy drugs and an immunotherapy drug, followed by targeted radiation, in people with bile duct or gallbladder cancer that cannot be removed with surgery. The goal is to see if this approach can shrink tumors and improve outcomes.
Nanjing, JiangsuAges 18–80 - NCT06543069RecruitingPhase 2
Combination therapy for unresectable peritoneal mesothelioma
This trial tests a combination of four drugs (sintilimab, bevacizumab, pemetrexed, and cisplatin) to see if they can shrink or control peritoneal mesothelioma that cannot be surgically removed. It may be an option if you have this rare cancer and are in fairly good health.
BeijingAges 18 years+ - NCT06555471RecruitingPhase 2
Sintilimab plus chemo-radiation for older adults with advanced stomach cancer
This trial tests whether adding the immunotherapy drug sintilimab to standard chemoradiotherapy can help people aged 75 or older with locally advanced stomach cancer. It aims to shrink tumors and improve outcomes.
Nanjing, JiangsuAges 75 years+ - NCT05495152RecruitingPhase 3
Sintilimab after esophageal surgery to help prevent cancer return
This trial looks at adding sintilimab (an immunotherapy) after surgery for certain stages of esophageal squamous cell cancer. The goal is to lower the chance the cancer comes back after standard treatment.
Zhengzhou, HenanAges 18–70 - NCT07722754RecruitingPhase 2
Combination therapy for advanced colorectal cancer
This trial tests a combination of four drugs—bevacizumab, sintilimab, cetuximab, and irinotecan—in people whose colorectal cancer has spread and hasn't responded to previous treatments. The goal is to see if this new mix can shrink tumors or slow the cancer's growth.
Guangzhou, GuangdongAges 18–75 - NCT07692152RecruitingPhase 3
Immunotherapy vs. chemo for MS anal cancer trial
This trial tests sintilimab (a type of immunotherapy) against mitomycin plus chemotherapy with radiation for anal cancer that hasn't spread. It aims to find a better treatment with fewer side effects.
Beijing, Beijing MunicipalityAges 18–75 - NCT07683221RecruitingPhase 2
Combination treatment for locally advanced pancreatic cancer
This trial tests a new combination of drugs with radiation therapy for people with locally advanced pancreatic cancer that cannot be removed with surgery. The treatment aims to shrink the tumor and improve outcomes.
Jinan, ShandongAges 18–75 - NCT06664996RecruitingPhase 2
Immunotherapy plus radiation before surgery for liver cancer with portal vein tumor clot
This trial tests combining an immunotherapy drug (sintilimab) with focused radiation (SBRT) before surgery for liver cancer that has spread into a branch of the portal vein. The goal is to see if this combination can shrink the tumor and make surgery more successful.
Chengdu, SichuanAges 18 years+ - NCT04973293Recruiting
Pre-surgery immunotherapy plus chemo and blood-vessel medicine for lung cancer
This study tests whether giving sintilimab (an immune therapy) combined with bevacizumab (a blood-vessel–targeting medicine) plus chemotherapy before surgery can improve outcomes for resectable lung cancer. It’s meant for people with specific lung cancer types and good health for surgery, and it avoids certain cancer types and immune-related risks.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05979818RecruitingPhase 1
Propranolol plus immunotherapy and chemo for advanced lung cancer
This trial tests adding a beta-blocker (propranolol) to a combination of immunotherapy (sintilimab) and standard chemotherapy for people with advanced non-small cell lung cancer that hasn't been treated before. The goal is to see if this new triple treatment helps shrink tumors better than chemo-immunotherapy alone.
Changsha, HunanAges 18–75 - NCT06685276RecruitingPhase 2
Combination therapy for advanced colorectal cancer
This trial tests a combination of three drugs (fruquintinib, chidamide, and sintilimab) for people with a specific type of metastatic colorectal cancer that has not responded to at least two prior treatments. It aims to see if this combination is safe and effective.
BeijingAges 18–75 - NCT06709417RecruitingPhase 2
Immunotherapy plus chemo and radiation for advanced esophageal cancer
This trial is testing whether giving a combination of an immunotherapy drug (sintilimab) with chemotherapy, followed by radiation plus more chemotherapy (concurrent chemoradiotherapy), can help people with advanced esophageal cancer that cannot be removed surgically. The goal is to see if this approach shrinks the tumor and improves outcomes.
Shanghai, Shanghai MunicipalityAges 20–75 - NCT06718205RecruitingPhase 2
Nimotuzumab plus immunotherapy and chemo for esophageal cancer
This study tests a new combination of drugs for advanced esophageal cancer. It adds an antibody (nimotuzumab) and an immunotherapy (sintilimab) to standard chemotherapy, aiming to improve how well treatment works.
Zhengzhou, HenanAges 18–75 - NCT07581821RecruitingPhase 2
Immunotherapy plus targeted drugs for advanced nasopharyngeal cancer
This trial tests a combination of three drugs (sintilimab, anlotinib, and chemotherapy) for nasopharyngeal cancer that has returned or spread after initial treatment. The goal is to see if this combination helps slow or shrink the cancer.
Zhuhai, GuangdongAges 18–65 - NCT07560488RecruitingPhase 2
Immunotherapy and Chemotherapy Combination for Advanced Liver Cancer
This trial tests a combination of four treatments (two immunotherapy drugs, a blood-vessel-blocking drug, and chemotherapy delivered directly to the liver) to shrink unresectable (inoperable) advanced liver cancer and potentially make it removable by surgery. The goal is to help patients who have never had cancer treatment before.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT06558227RecruitingPhase 2
ZG005 with bevacizumab vs sintilimab with bevacizumab for advanced liver cancer
This trial tests a new drug combination (ZG005 plus bevacizumab) against a standard combination (sintilimab plus bevacizumab) in people with advanced liver cancer that has spread or cannot be surgically removed. The goal is to see which combination works better and is safe.
Chengdu, SichuanAges 18–75 - NCT07557251RecruitingPhase 1
Combination immunotherapy for advanced liver cancer with hepatitis B
This trial tests a new combination of three drugs (BRII-5395, sintilimab, and bevacizumab) for advanced hepatocellular carcinoma (liver cancer) in patients with hepatitis B who have not responded well to previous treatments. The goal is to evaluate whether this combination is safe and effective.
BeijingAges 18–70 - NCT04840355Recruiting
Monitoring safety of sintilimab in Chinese patients
This study carefully tracks how safe sintilimab is for people with cancer in real-world care. It may help your care team understand side effects and risks during treatment.
Beijing, Beijing MunicipalityAges 18–75 - NCT06054906RecruitingPhase 2
Immunotherapy plus chemo before surgery for stomach cancer
This trial tests a combination of an immunotherapy drug (sintilimab) and a low-dose weekly chemotherapy regimen before surgery for locally advanced stomach cancer that can be removed. The goal is to see if this approach helps shrink the tumor and improve outcomes.
ShanghaiAges 18 years+
Common questions
- Are there clinical trials studying Sintilimab?
- Yes. Clin2 currently lists 172 recruiting studies that include Sintilimab, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Sintilimab trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Sintilimab an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Sintilimab or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.